Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

.blurhash-client-img { display: none !important; }

Open Access

|Nov 2021

Authors

Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia

University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia

University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia

Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia

Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia

Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia

University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

DOI: https://doi.org/10.2478/raon-2021-0044 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Language: English

Page range: 482 - 490

Submitted on: Aug 19, 2021

Accepted on: Oct 7, 2021

Published on: Nov 19, 2021

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Related subjects:

© 2021 Martina Vrankar, Karmen Stanic, Stasa Jelercic, Eva Ciric, Ana Lina Vodusek, Jasna But-Hadzic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.